Today's guideline for the assessment of cardiovascular risks and the treatment of blood cholesterol to reduce atherosclerotic cardiovascular diseases (ASCVD) is demonstrated. However, there is a lack of information about available data regarding the relationship between coronary artery calcium score (CACS) using multidetector computed tomography (MDCT) and statin-intensity class of drugs in asymptomatic healthy individuals.Design and Method:
According to the new guidelines of 2013, all participants (n = 3,817, male: female 2,649: 1,265, mean age: 55 ± 10 years; age 40 to 79 years) in the present study were categorized into three groups by the statin-intensity class of drugs: high-intensity (n = 1,284, 32.8%); moderate-intensity (n = 1,602, 40.9%) and low-intensity statin therapy group (n = 931, 23.8%). We analyzed the relationship between CACS and the statin benefit group. The statin benefit group was defined as individuals who should be considered moderate- and high-intensity statin therapy.Results:
The ten-year ASCVD (12.6 ± 5.3% vs. 2.9 ± 1.9%, P < 0.001) and CACS (98 ± 270 vs. 3 ± 2, P < 0.001) were significant higher in the high-intensity group than in moderate-intensity statin therapy group. In the high-intensity statin therapy group, age [odds ratio: 1.299 (1.137–1.483), P < 0.001], male gender [odds ratio: 44.252 (1.959–999.784), P = 0.001], and fasting blood glucose [odds ratio: 1.046 (1.007–1.087), P = 0.021] were independent risk factors associated with CACS ≥ 300 by multivariate logistic regression analysis.Conclusions:
CACS as well as global risk scores plays an important role as a complementary tool for the cardiovascular risk stratification and more specific strategies of statin therapy should be considered in an asymptomatic individual, especially if a high-intensity statin therapy is required.